英国肌少症登记系统SarcNet试点:招募可行性与基线特征
该研究在英国6个中心测试建立肌少症登记系统的可行性,通过基层邮件邀请65岁以上人群,经SARC-F电话初筛后现场评估。共发出3508封信,应答率12%,最终招募150人,其中94%符合EWGSOP 2019 probable肌少症标准,98%同意未来再联系。邮件加大学标识未显著影响应答率。
要点
- 多中心肌少症登记系统招募可行,再联系同意率高达98%。
- 电话SARC-F初筛后仅57%符合现场评估条件。
- 入组者平均78岁,94%符合EWGSOP 2019 probable肌少症标准。
核心结论
- 在英国建立多中心肌少症登记系统是可行的,且参与者对未来研究再联系的同意率很高。
研究设计与样本
- 研究为可行性试点研究,涉及英国6个中心,通过基层邮件邀请65岁及以上人群,并进行电话SARC-F初筛和现场基线评估。
主要发现
- 共收到428封回复,应答率12%;380人接受电话初筛,其中215人(57%)符合现场评估条件;最终招募150人(占初筛者的40%)。
- 邮件加大学标识与不加标识的应答率无显著差异,组间差1.1%(95%CI -1.0%至3.4%),P=0.31。
- 入组者平均年龄78岁,女性72人(49%);138/147(94%)符合EWGSOP 2019 probable肌少症标准;145/147(98%)同意未来再联系。
关键数值与推荐
- 肌少症评估采用欧洲老年人肌少症工作组(EWGSOP)2019标准,probable肌少症比例为138/147(94%)。
- 电话初筛采用SARC-F评分,现场评估包括握力、简易体能状况量表(SPPB)、生物电阻抗分析、老年抑郁量表、蒙特利尔认知评估和肌少症生活质量评分。
临床怎么用
- 老年医学科可借鉴该登记系统模式,通过基层邮件邀请和电话SARC-F初筛招募肌少症研究参与者。
- 高再联系同意率支持建立肌少症患者队列用于未来干预研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: sarcopenia registries are a potential method to meet the challenge of recruitment to sarcopenia trials. We tested the feasibility of setting up a UK sarcopenia registry, the feasibility of recruitment methods and sought to characterise the pilot registry population. METHODS: six diverse UK sites took part, with potential participants aged 65 and over approached via mailshots from local primary care practices. Telephone pre-screening using the SARC-F score was followed by in-person screening and baseline visit. Co-morbidities, medications, grip strength, Short Physical Performance Battery, bioimpedance analysis, Geriatric Depression Score, Montreal Cognitive Assessment, Sarcopenia Quality of Life score were performed and permission sought for future recontact. Descriptive statistics for recruitment rates and baseline measures were generated; an embedded randomised trial examined the effect of a University logo on the primary care mailshot on recruitment rates. RESULTS: sixteen practices contributed a total of 3,508 letters. In total, 428 replies were received (12% response rate); 380 underwent telephone pre-screening of whom 215 (57%) were eligible to attend a screening visit; 150 participants were recruited (40% of those pre-screened) with 147 contributing baseline data. No significant difference was seen in response rates between mailshots with and without the logo (between-group difference 1.1% [95% confidence interval -1.0% to 3.4%], P = 0.31). The mean age of enrollees was 78 years; 72 (49%) were women. In total, 138/147 (94%) had probable sarcopenia on European Working Group on Sarcopenia 2019 criteria and 145/147 (98%) agreed to be recontacted about future studies. CONCLUSION: recruitment to a multisite UK sarcopenia registry is feasible, with high levels of consent for recontact.
引用
- Witham MD, Heslop P, Dodds RM, et al. Developing a UK sarcopenia registry: recruitment and baseline characteristics of the SarcNet pilot. Age Ageing. 2021. PMID: 34038519. doi:10.1093/ageing/afab084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。